Literature DB >> 36105035

Short- and long-term efficacy of sustained-release chemotherapy in tumor bed interstitium combined with surgical resection for recurrent malignant glioma.

Longlong Wang1, Zhifeng Wang1, Zan Liang1, Guojing Li1, Shibo Duan1, Yanguo Xi1.   

Abstract

OBJECTIVE: To discuss and analyze the short- and long-term curative effect of sustained-release chemotherapy combined with surgical resection on recurrent malignant glioma.
METHODS: The clinical data of 137 patients with recurrent glioma admitted to our hospital from March 2016 to July 2018 were retrospectively analyzed. Among them, 67 patients who received local chemotherapy with cisplatin slow-release polymer after surgical resection were included in the observation group, and the other 70 patients who did not receive chemotherapy after surgical resection were regarded as the control group. The short-term therapeutic efficacy, quality of life score before and after surgery, incidence of toxic and side effects, long-term recurrence rate and survival were compared between the two groups.
RESULTS: The total remission rate of clinical treatment in observation group was remarkably higher than that in control group (P<0.05). There was no statistically significant difference in quality of life score between the two groups before and after surgery (P>0.05). There was no significant difference in the incidence of postoperative side effects between the two groups (P>0.05). While the recurrence rates of the observation group at 12 and 24 months after surgery were significantly lower than those in the control group (P<0.05). The overall postoperative survival of observation group was obviously superior to that of control group (P<0.05). In patients who received sustained-release chemotherapy in tumor bed interstitium combined with surgical resection, older ones and the ones with partial surgical resection or pathological grade IV had worse long-term survival (P<0.05).
CONCLUSION: The combined treatment of sustained release chemotherapy in tumor bed interstitium and surgical resection for recurrent malignant glioma can effectively improve the clinical efficacy, reduce postoperative recurrence rate and prolong the survival time of the patients. AJTR
Copyright © 2022.

Entities:  

Keywords:  Sustained release chemotherapy; long-term efficacy; malignant glioma; recurrent; short-term efficacy; surgical resection; tumor bed interstitium

Year:  2022        PMID: 36105035      PMCID: PMC9452319     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   3.940


  29 in total

1.  Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq.

Authors:  Andrew S Venteicher; Itay Tirosh; Christine Hebert; Keren Yizhak; Cyril Neftel; Mariella G Filbin; Volker Hovestadt; Leah E Escalante; McKenzie L Shaw; Christopher Rodman; Shawn M Gillespie; Danielle Dionne; Christina C Luo; Hiranmayi Ravichandran; Ravindra Mylvaganam; Christopher Mount; Maristela L Onozato; Brian V Nahed; Hiroaki Wakimoto; William T Curry; A John Iafrate; Miguel N Rivera; Matthew P Frosch; Todd R Golub; Priscilla K Brastianos; Gad Getz; Anoop P Patel; Michelle Monje; Daniel P Cahill; Orit Rozenblatt-Rosen; David N Louis; Bradley E Bernstein; Aviv Regev; Mario L Suvà
Journal:  Science       Date:  2017-03-31       Impact factor: 47.728

Review 2.  Assessment of efficacy of dendritic cell therapy and viral therapy in high grade glioma clinical trials. A meta-analytic review.

Authors:  Bogdan Ionel Vatu; Stefan-Alexandru Artene; Adeline-Georgiana Staicu; Adina Turcu-Stiolica; Catalin Folcuti; Alexandra Dragoi; Catalina Cioc; Stefania-Carina Baloi; Ligia Gabriela Tataranu; Cristian Silosi; Anica Dricu
Journal:  J Immunoassay Immunochem       Date:  2018-11-30

3.  Heterogeneous Glioma Cell Invasion Under Interstitial Flow Depending on Their Differentiation Status.

Authors:  Naoko Namba; Yuta Chonan; Takehito Nunokawa; Oltea Sampetrean; Hideyuki Saya; Ryo Sudo
Journal:  Tissue Eng Part A       Date:  2021-02-15       Impact factor: 3.845

Review 4.  The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma-Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses.

Authors:  Russell Maxwell; Andrew S Luksik; Tomas Garzon-Muvdi; Michael Lim
Journal:  Curr Neurol Neurosci Rep       Date:  2017-06       Impact factor: 5.081

5.  Characterization of primary glioma cell lines derived from the patients according to 2016 CNS tumour WHO classification and comparison with their parental tumours.

Authors:  Maria Antonietta Oliva; Sabrina Staffieri; Salvatore Castaldo; Felice Giangaspero; Vincenzo Esposito; Antonietta Arcella
Journal:  J Neurooncol       Date:  2021-01-04       Impact factor: 4.130

6.  Adipocyte enhancer binding protein 1 (AEBP1) knockdown suppresses human glioma cell proliferation, invasion and induces early apoptosis.

Authors:  Limin Cheng; Xuefei Shao; Qifu Wang; Xiaochun Jiang; Yi Dai; Sansong Chen
Journal:  Pathol Res Pract       Date:  2019-12-17       Impact factor: 3.250

7.  The necessity for standardization of glioma stem cell culture: a systematic review.

Authors:  Lei Zhang; Hongwei Yu; Yuhui Yuan; John S Yu; Zhenkun Lou; Yixue Xue; Yunhui Liu
Journal:  Stem Cell Res Ther       Date:  2020-02-26       Impact factor: 6.832

8.  Neutrophil extracellular traps mediate the crosstalk between glioma progression and the tumor microenvironment via the HMGB1/RAGE/IL-8 axis.

Authors:  Caijun Zha; Xiangqi Meng; Lulu Li; Shan Mi; Da Qian; Ziwei Li; Pengfei Wu; Shaoshan Hu; Shihong Zhao; Jinquan Cai; Yanhong Liu
Journal:  Cancer Biol Med       Date:  2020-02-15       Impact factor: 4.248

9.  MicroRNA‑138 modulates glioma cell growth, apoptosis and invasion through the suppression of the AKT/mTOR signalling pathway by targeting CREB1.

Authors:  Chi Zhang; Qi Wang; Xiaowen Zhou; Lei Zhang; Ying Yao; Juan Gu; Huairui Chen; Jun Qian; Chun Luo; Qingke Bai; Guohan Hu
Journal:  Oncol Rep       Date:  2020-10-15       Impact factor: 3.906

10.  Increased Radiation-Associated T-Cell Infiltration in Recurrent IDH-Mutant Glioma.

Authors:  Anastasia Makarevic; Carmen Rapp; Steffen Dettling; David Reuss; Christine Jungk; Amir Abdollahi; Andreas von Deimling; Andreas Unterberg; Christel Herold-Mende; Rolf Warta
Journal:  Int J Mol Sci       Date:  2020-10-21       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.